Management & Regulatory

EU Pharmaceutical Reforms: Impacts on Biopharma and Innovation
Management & Regulatory EU Pharmaceutical Reforms: Impacts on Biopharma and Innovation

The winds of change are coursing through the corridors of the European Union (EU) institutions as sweeping reforms to pharmaceutical legislation are poised to redefine the biopharmaceutical playing field. Originating from the European Commission's Pharmaceutical Strategy for Europe, these

Sunshine Biopharma's Turbulent Year: Growth to Steep Decline
Management & Regulatory Sunshine Biopharma's Turbulent Year: Growth to Steep Decline

In the dynamic landscape of the stock market, few stories encapsulate the sheer unpredictability like that of Sunshine Biopharma Inc. (SBFM). From dizzying peaks to harrowing valleys, SBFM's fiscal journey over the past year reads like a thrilling financial epic. With the highest crest at

AI in Biopharma: Balancing Efficiency with Sustainability
Management & Regulatory AI in Biopharma: Balancing Efficiency with Sustainability

The biopharmaceutical industry is at a critical juncture, facing the pressing need to incorporate sustainability into its growth and innovation strategies. The rise of artificial intelligence (AI) presents both opportunities and challenges in this quest. While AI has demonstrated a profound ability

How Are Biopharma Layoffs Shaping Industry's Future?
Management & Regulatory How Are Biopharma Layoffs Shaping Industry's Future?

The biopharmaceutical industry is experiencing a profound transformation, marked by a wave of layoffs and strategic overhauls across companies of all sizes. Confronted with economic headwinds and the urgency to adapt, biopharma entities are taking decisive steps to shore up their operations. This

How Are Pharma Companies Enhancing Sustainability?
Management & Regulatory How Are Pharma Companies Enhancing Sustainability?

The pharmaceutical industry confronts a pivotal moment as the imperative to integrate sustainability throughout supply chains gains momentum. Amid shifting paradigms, companies are increasingly aware that business success is no longer measured solely in financial terms. Today's corporate

Merck to Buy Mirus Bio in $600M Deal to Boost Gene Therapy
Biotech & Bioprocessing Merck to Buy Mirus Bio in $600M Deal to Boost Gene Therapy

In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later